Preclinical evaluation of tridecaptin M: in vitro and in vivo efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01083-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Vrushali Raka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India. Hauptthemen laut MEDLINE: Colistin, Anti-Bacterial Agents, Klebsiella pneumoniae, Escherichia coli. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
The escalating threat of antimicrobial resistance (AMR), particularly among gram-negative pathogens, necessitates the development of novel therapeutic agents. Tridecaptins, a class of non-ribosomally synthesized lipopeptides with a novel mode of action, have garnered renewed interest in the fight against AMR. Our group previously identified tridecaptin M, a compound with a promising safety profile, prompting further investigation into its efficacy and preclinical characteristics. Here, we show that tridecaptin M exhibits potent activity against multidrug-resistant (MDR) Klebsiella pneumoniae and Escherichia coli without cross-resistance to colistin. It effectively inhibits biofilm formation and disrupts 50% of established biofilm at 10 µg/mL. Tridecaptin M demonstrates a favorable safety profile, as it does not inhibit the cardiac hERG channel and shows minimal interaction with cytochrome P450 enzymes, with no IC₅₀ detected up to 44.6 µg/mL. In vivo toxicity studies via subcutaneous administration confirm its safety up to 600 mg/kg, whereas intravenous administration reveals acute toxicity at ≥30 mg/kg, with biochemical evidence of skeletal muscle, cardiac, and hepatic involvement. In mouse infection models using a colistin-resistant MDR strain of K. pneumoniae reveal the in vivo potential of tridecaptin M and a dose-dependent efficacy at 10 mg/kg, 20 mg/kg, 50 mg/kg, and 100 mg/kg doses, showing a non-linear relationship. Tridecaptin M is metabolized by liver microsomes, with low clearance, and pharmacokinetic analysis in rats indicates favorable attributes, with a terminal half-life (T₁/₂) of 3.65 h intravenously and 8.81 h subcutaneously. Collectively, these data support the continued preclinical development of tridecaptin M as a promising candidate for treating severe gram-negative infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Microbiology & Antimicrobial Research Laboratory, CSIR-Institute of Microbial Technology, Chandigarh, India.
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
- Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Vrushali Raka, Shubhangi Kansal, Hemraj Nandanwar
Förderung
- Council of Scientific and Industrial Research, India
Zitieren
APA
Raka, V., Jangra, M., Kaur, P., Dadwal, R., Kansal, S., Angrup, A., Ray, P., & Nandanwar, H. (2025). Preclinical evaluation of tridecaptin M: in vitro and in vivo efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01083-25
Vancouver
Raka V, Jangra M, Kaur P, Dadwal R, Kansal S, Angrup A, et al. Preclinical evaluation of tridecaptin M: in vitro and in vivo efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01083-25
BibTeX
@article{Raka2025,
author = {Raka, Vrushali and Jangra, Manoj and Kaur, Parminder and Dadwal, Rajneesh and Kansal, Shubhangi and Angrup, Archana and Ray, Pallab and Nandanwar, Hemraj},
title = {Preclinical evaluation of tridecaptin M: in vitro and in vivo efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01083-25}
}
EUVIMED